Coeptis Therapeutics (COEP) Insider Trading & Ownership $0.14 0.00 (-2.08%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Coeptis Therapeutics (NASDAQ:COEP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage24.25%Number OfInsiders Buying(Last 12 Months)5Amount OfInsider Buying(Last 12 Months)$36,841.92Number OfInsiders Selling(Last 12 Months)0 Get COEP Insider Trade Alerts Want to know when executives and insiders are buying or selling Coeptis Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address COEP Insider Buying and Selling by Quarter Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Coeptis Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/12/2024Tara DesilvaDirectorBuy2,266$0.58$1,314.28 1/10/2024Brian CogleyCFOBuy5,000$0.67$3,350.00 1/8/2024David MehalickCEOBuy20,004$0.66$13,202.64 1/5/2024Daniel Alexander YeraceVPBuy10,850$0.69$7,486.50 1/5/2024David MehalickCEOBuy5,050$0.69$3,484.50 1/5/2024Gene SalkindDirectorBuy11,600$0.69$8,004.00 (Data available from 1/1/2013 forward) COEP Insider Trading Activity - Frequently Asked Questions Who is on Coeptis Therapeutics's Insider Roster? The list of insiders at Coeptis Therapeutics includes Brian Cogley, Chris Calise, Daniel Alexander Yerace, David Mehalick, Gene Salkind, and Tara Desilva. Learn more on insiders at COEP. What percentage of Coeptis Therapeutics stock is owned by insiders? 24.25% of Coeptis Therapeutics stock is owned by insiders. Learn more on COEP's insider holdings. Which Coeptis Therapeutics insiders have been buying company stock? The following insiders have purchased COEP shares in the last 24 months: Brian Cogley ($3,350.00), Chris Calise ($10,887.08), Daniel Alexander Yerace ($7,486.50), David Mehalick ($16,687.14), Gene Salkind ($38,110.64), and Tara Desilva ($1,314.28). How much insider buying is happening at Coeptis Therapeutics? Insiders have purchased a total of 98,996 COEP shares in the last 24 months for a total of $77,835.64 bought. Coeptis Therapeutics Key ExecutivesMr. David Mehalick (Age 55)Co-Founder, Chairman of the Board, CEO & President Compensation: $360kMs. Christine Elise Sheehy (Age 56)Co-Founder and VP of Compliance & Corporate Secretary Compensation: $151kMr. Daniel Alexander Yerace (Age 41)Co-Founder, VP of Operations & Director Compensation: $360kMr. Brian Cogley M.B.A. (Age 37)Chief Financial Officer Compensation: $208kDr. Colleen Delaney M.D. (Age 56)M.Sc., CSO & Chief Medical Officer Compensation: $360k More Insider Trading Tools from MarketBeat Related Companies RenovoRx Insider Trades ProMIS Neurosciences Insider Trades LianBio Insider Trades Forte Biosciences Insider Trades DURECT Insider Trades KALA BIO Insider Trades Longeveron Insider Trades Lipocine Insider Trades Pluri Insider Trades MiNK Therapeutics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:COEP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.